{
  "report_rows": [
    {
      "kpi": "Medical Benefit Ratio (MBR)",
      "prediction": "BEAT",
      "answer": "pred ~88.7% vs. cons 89.2%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "HCB Adj. Operating Income",
      "prediction": "BEAT",
      "answer": "pred ~$1.60B vs. cons $1.48B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EPS (Diluted, Operating)",
      "prediction": "BEAT",
      "answer": "pred ~$1.97 vs. cons $1.87",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Adj. EPS (FY2026)",
      "prediction": "BETTER",
      "answer": "guide ~$7.55-$7.75 vs. cons $7.47",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 MBR (FY2026)",
      "prediction": "BETTER",
      "answer": "guide ~90.0-90.5% vs. cons 90.2%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Revenue (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "guide >=407B vs. cons $407.6B",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 4.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 H2 estimate revisions drive continued buying as sell-side models update; fades from Day-1 peak given elevated stock price",
  "day5_confidence": "MEDIUM"
}